Suzhou Forlong Biotechnology Co., Ltd
4 clinical trials · Sponsor
◉ Watch Suzhou Forlong Biotechnology Co., Ltd
| Record | Firm | Date |
|---|---|---|
| A Study of FL115 in Combination With a PD-1 Antibody in Advanced Solid Tumors (NCT07131202) | Suzhou Forlong Biotechnology Co., Ltd | 2026-01-08 |
| A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer (NCT07122414) | Suzhou Forlong Biotechnology Co., Ltd | 2024-08-16 |
| A Study of FL115 Monotherapy in Unresectable or Metastatic Solid Tumors (NCT07131189) | Suzhou Forlong Biotechnology Co., Ltd | 2024-05-30 |
| First-in-Human, Phase I, Open-label, Multicenter, Dose Escalation Clinical Study (NCT06130722) | Suzhou Forlong Biotechnology Co., Ltd | 2023-12-30 |
Track Suzhou Forlong Biotechnology Co., Ltd automatically
Every clearance here is in the API, with alerts when new ones post.